# Johns Hopkins University NCTN Lead Academic Site Program

> **NIH NIH UG1** · JOHNS HOPKINS UNIVERSITY · 2021 · $598,199

## Abstract

Project Summary
 Johns Hopkins has been an academic member institution of cooperative groups since
the founding of this national oncology research in 1955. Over the decades, our faculty have
provided strong clinical and laboratory scientific leadership, and administrative leadership to the
cooperative groups. Our primary goal is to provide scientific leadership thus bringing innovative
translational science developed in pre-clinical and early phase trials at Johns Hopkins via
mechanisms such as the ETCTN to the National Clinical Trials Network (NCTN) for further
development. Our faculty serve in leadership roles as study PIs and laboratory PIs, disease
and modality committee chairs. The majority of our contributions and our longest association
remains with ECOG-ACRIN and secondly with NRG. The specific aims for our grant are 1) To
provide scientific leadership within the NCTN groups and their disease-oriented committees. 2)
To bring correlative translational research, novel imaging and radiation techniques, cell biology
and molecular biology, into clinical trials for all stages of cancer. 3) To strengthen and enhance
the coordinated, collaborative, and inclusive infrastructure established under one administrative
program in order to support NCTN projects and promote participation in order NCI-supported
projects, such as the ETCTN. 4) To address the challenges of supporting participation and
accrual across disciplines, modalities, rare and diverse patient populations at all Johns Hopkins
Kimmel Cancer Center locations. 5) To promote the involvement of junior faculty in all our aims
for their advancement and contribution to the NCI cancer program. These goals will be
accomplished through the mission of the Johns Hopkins Kimmel Cancer Center. The Center
has achieved excellence in translational research through program project, RO1, and SPORE
grants. In addition, early clinical trials of new drugs are conducted under the NCI phase I
contract (since 1982). Also the ETCTN grant allows the development of early phase trials that
incorporate novel biomarkers of activity in order to advance new treatments in the field. Johns
Hopkins investigators have focused on enhancing minority participation in clinical trials through
grants as well as increasing overall clinical trial accrual throughout Johns Hopkins Kimmel
Cancer Center sites.

## Key facts

- **NIH application ID:** 10107780
- **Project number:** 5UG1CA233196-03
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** DEBORAH K ARMSTRONG
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $598,199
- **Award type:** 5
- **Project period:** 2019-03-06 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10107780

## Citation

> US National Institutes of Health, RePORTER application 10107780, Johns Hopkins University NCTN Lead Academic Site Program (5UG1CA233196-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10107780. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*